Episode 1 - CRPC: Recent Advances and Paradigm Shifts in Treatment

During the opening segment of this panel discussion about recent advances and pharmacoeconomic considerations in the clinical management of Castration-Resistant Prostate Cancer (CRPC), discussion moderator Raoul S. Concepcion, MD, is joined by expert panelists David Crawford, MD, Jeffrey D. Dunn, PharmD, MBA, Michael Kolodziej, MD, and David Quinn, MD.

After the panelists briefly introduce themselves and explain their relationships to medical oncology, Dr Concepcion cites important statistics about the economic and clinical burden of CRPC.

Dr Quinn reviews the treatment landscape for CRPC and explains how a paradigm shift in the US Food and Drug Administration’s approval of agents to treat CRPC has improved the disease’s outlook.